Impact of Hyperglycemia on Survival and Infection-Related Adverse Events in Patients with Metastatic Colorectal Cancer Who Were Receiving Palliative Chemotherapy

Yong Joo Hong; Hye-Suk Han; Yusook Jeong; Jiwon Jeong; Sung-Nam Lim; Hyung Jin Choi; Hyun-Jung Jeon; Tae-Keun Oh; Sang-Jeon Lee; Ki Hyeong Lee

doi:10.4143/crt.2014.46.3.288

Articles

Page Path: HOME > Cancer Res Treat > Volume 46(3); 2014 > Article

Original Article Impact of Hyperglycemia on Survival and Infection-Related Adverse Events in Patients with Metastatic Colorectal Cancer Who Were Receiving Palliative Chemotherapy: Yong Joo Hong, MD¹, Hye-Suk Han, MD, PhD^1,, Yusook Jeong, MD¹, Jiwon Jeong, MD¹, Sung-Nam Lim, MD¹, Hyung Jin Choi, MD¹, Hyun-Jung Jeon, MD¹, Tae-Keun Oh, MD¹, Sang-Jeon Lee, MD², Ki Hyeong Lee, MD¹; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2014;46(3):288-296.
DOI: https://doi.org/10.4143/crt.2014.46.3.288
Published online: July 15, 2014

¹Departments of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea

²Departments of Surgery, Chungbuk National University College of Medicine, Cheongju, Korea

Correspondence: Hye-Suk Han, MD, PhD Department of Internal Medicine, Chungbuk National University College of Medicine, 776 1-sunhwan-ro, Heungdeok-gu, Cheongju 361-711, Korea
Tel: 82-43-269-6306 Fax: 82-43-273-3252 E-mail: sook3529@hanmail.net

• Received: July 1, 2013 • Accepted: October 8, 2013

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

12,209 Views
72 Download
7 Web of Science
6 Crossref
8 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
Non-metastatic colorectal cancer patients with diabetes have poor overall survival than those without diabetes. However, the effect of hyperglycemia on survival after diagnosis of metastatic colorectal cancer (CRC) has not been assessed. Therefore, we assessed the impact of hyperglycemia on the survival and infection-related adverse events (AEs) in patients with metastatic CRC.
Materials and Methods
We reviewed the records of 206 patients with newly diagnosed metastatic CRC who were treated with palliative chemotherapy from March 2000 to December 2012 at Chungbuk National University Hospital. The mean glucose level of each patient was calculated using all available glucose results.
Results
The mean glucose levels ranged between 76.8 and 303.5 mg/dL, and patients were categorized into quartiles in accordance to their mean glucose level: group 1 (< 106.7 mg/dL), group 2 (106.7-117.2 mg/dL), group 3 (117.3-142.6 mg/dL), and group 4 (> 142.6 mg/dL). The median overall survival for patients in groups 1, 2, 3, and 4 were 22.6, 20.1, 18.9, and 17.9 months, respectively; however, this difference was not statistically significant (p=0.643). Compared with patients in group 1, those in groups 2, 3, and 4 were at a higher risk of infection-related AEs, according to a multivariate analysis (p=0.002).
Conclusion
Hyperglycemia was not associated with shorter survival; however, it was associated with infection-related AEs in patients with newly diagnosed metastatic CRC receiving palliative chemotherapy.
Key words: Colorectal neoplasms, Hyperglycemia, Infection, Survival

Introduction

The prevalence of diabetes mellitus (DM) and cancer has steadily increased as people live longer [1,2]. Indeed, many patients with pre-existing DM may develop cancer, and cancer patients often develop DM. Epidemiologic evidence suggests that individuals with DM are at a significantly higher risk of many forms of cancer, such as liver, pancreatic, colorectal, breast, renal, bladder, and endometrial cancer [3]. A 10-year prospective cohort study of 1,298,385 Koreans, who received health insurance from the National Health Insurance Corporation, showed that an elevated fasting serum glucose level and a diagnosis of DM are independent risk factors for several major cancers, and the risk tended to increase as the fasting serum glucose level increased [4]. The association between DM and colorectal cancer (CRC) has been extensively studied. Convincing evidence from previous studies, including a large meta-analysis, suggested that individuals with DM are at a higher risk of developing CRC [5]. Evidence also suggests that DM is associated with an increased risk of CRC mortality, and diabetic patients with CRC have poorer overall survival than non-diabetic patients with CRC [6-8]. A recent study from the Cancer Prevention Study-II (CPS-II) Nutrition Cohort showed that patients with non-metastatic CRC and type 2 DM have a higher risk of death from all causes, including CRC and cardiovascular disease, than patients with non-metastatic CRC and without type 2 DM [7].

DM and hyperglycemia are not only common in nonmetastatic CRC patients, but also in metastatic CRC patients. Moreover, patients with metastatic CRC are at a higher risk of hyperglycemia because their supportive treatment routinely includes high-dose glucocorticoids, such as dexamethasone (used as an antiemetic) and megestrol acetate (used as an appetite stimulant), which increase the plasma glucose level. Furthermore, hyperglycemia is associated with infectious complications in immunocompromised cancer patients, which may delay and decrease the efficacy of treatment and thus directly affect survival [9]. Although there are several reports that describe the association between diabetes and an outcome of patients with non-metastatic CRC, the impact of hyperglycemia on the outcome of patients with metastatic CRC has not been evaluated.

Therefore, we assessed the impact of hyperglycemia on the survival and infection-related adverse events (AEs) of patients with metastatic CRC, receiving palliative chemotherapy.

Materials and Methods

1. Study population

A retrospective chart review was performed on all patients with newly diagnosed metastatic CRC, who presented at Chungbuk National University Hospital between March 2000 and December 2012. Patients were included in this analysis if they had a histologically confirmed adenocarcinoma, a newly diagnosed metastatic CRC, and had received palliative chemotherapy. Patients were excluded if they died at the initial hospitalization, had not received palliative chemotherapy, had a non-adenocarcinoma histology, or had a history of another malignancy.

This study was reviewed and approved by the Institutional Review Board of Chungbuk National University Hospital.

2. Data collection

The baseline clinical and pathological characteristics of the patients at the time of metastatic CRC diagnosis were reviewed, including age, sex, Eastern Cooperative Oncology Group performance status (ECOG PS), body mass index (BMI), comorbidity conditions by Charlson Comorbidity Index (CCI) scale [10], pre-existing DM and hypertension, location of the primary tumor, and stage. We also collected the medical record information on palliative treatments, including chemotherapeutic agents, number of prior palliative chemotherapies, and the use of dexamethasone or megestrol acetate.

The mean glucose level of each patient was calculated using all available values collected during the follow-up. The fasting status of the patient at the time of testing was not known. Infection-related AEs were calculated by grade in accordance to the Common Terminology Criteria for Adverse Events ver. 4.0 (http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf). The overall survival was defined as the time from diagnosis of metastatic CRC to death from any cause and was censored at the date of the last contact for those who remained alive.

3. Statistical analysis

The means and standard deviations (SDs) of clinical characteristics were calculated. The characteristics of patients were compared using Student’s t-test for the means and chi-square test for categorical variables.

Survival curves were estimated using the Kaplan-Meier method, which were compared using the log rank test. Infection- related AEs of patients were compared using the Fisher’s exact test. Multivariate logistic regression analysis with a backward stepwise method was used to evaluate the effects of hyperglycemia on the development of infection-related AEs. p-values of < 0.05 were considered statistically significant. All statistical analyses were performed using SPSS ver. 15.0 (SPSS Inc., Chicago, IL).

Results

1. Baseline patient characteristics

A total of 206 patients with newly diagnosed metastatic CRC, receiving palliative chemotherapy, were included in the final analysis. The median age of patients was 61 years (range, 16 to 84 years), and 44 patients (21.4%) had DM at the time of metastatic CRC diagnosis. The mean±SD glucose level was 132.0±40.1 mg/dL and the mean±SD number of glucose measurements per patient was 20.5±13.5. The mean glucose levels ranged between 76.8 and 303.5 mg/dL (median, 117.4 mg/dL), and the patients were divided into quartiles according to their mean glucose level: group 1 (< 106.7 mg/dL), group 2 (106.7-117.2 mg/dL), group 3 (117.3-142.6 mg/dL), and group 4 (> 142.6 mg/dL). Table 1 shows the demographic and clinical characteristics of patients in each group. The mean age, comorbidity conditions by CCI scale, and incidence of DM increased from group 1 to group 4 (p=0.038, p=0.007, and p < 0.001 for trend, respectively). There were no differences in the distributions of ECOG PS, BMI, hypertension, location of primary tumor, tumor stage, use of chemotherapeutic agents, number of palliative chemotherapies, and the use of dexamethasone or megestrol acetate between the four groups.

2. Effect of mean glucose level on patient survival

After a median follow-up of 3.5 years, 144 deaths were identified in the cohort of 206 patients with metastatic CRC. Kaplan-Meier survival curves of patients in each of the four groups are shown in Fig. 1A. The median overall survival was 22.6 months in group 1, 20.1 in group 2, 18.9 months in group 3, and 17.9 months in group 4; however, this difference was not statistically significant (p=0.643). The estimated hazard ratios (HRs) were 1.06 for group 2 (95% confidence interval [CI], 0.68 to 1.66), 1.29 for group 3 (95% CI, 0.82 to 2.03), and 1.25 for group 4 (95% CI, 0.79 to 1.97). There was also no statistically significant difference in the overall survival between patients with pre-existing DM or those without pre-existing DM (Fig. 1B). The median overall survival among patients with pre-existing DM and without pre-existing DM was 20.5 months and 19.7 months, respectively (HR, 1.08; 95% CI, 0.73 to 1.59; p=0.707).

3. Effect of mean glucose level on infection-related AEs

The incidence of infection-related AEs among patients in each of the four groups is presented in Table 2. Compared with patients in group 1, those in groups 2, 3, and 4 were at higher risk of infection-related AEs, including any grade, grade 3 or grade 4 infection, and were more susceptible to hospitalization from infection (p=0.002, p=0.003, and p=0.025 for trend, respectively). The incidence of any grade of infection- related AEs was significantly affected by comorbidity conditions in accordance to the CCI scale, including pre-existing DM, use of dexamethasone and megesterol acetate, and the mean glucose level. However, duration of dexamethasone use and the mean glucose level were the only significant factors for the incidence of infection-related AEs (p=0.008 and p=0.002, respectively). Other clinical characteristics were not significant factors for the incidence of infection- related AEs, according to a multivariate analysis (Table 3).

Discussion

This study showed that hyperglycemia is not associated with shorter survival in patients with newly diagnosed metastatic CRC receiving palliative chemotherapy. However, infection-related AEs increased with an increase in the mean glucose level.

Recent large cohort studies suggest that pre-existing diabetes at the time of cancer diagnosis is associated with increased all-cause mortality and cancer recurrence, especially in patients with colon and breast cancers [6-9,11,12]. Several explanations are proposed for the association between pre-existing diabetes and increased all-cause mortality in cancer patients. Firstly, cancer patients with diabetes may have increased tumor cell proliferation and metastases as a consequence of the physiological environment of hyperinsulinemia. It is possible that high insulin levels or an increase in free insulin-like growth factor levels in hyperinsulinemic states promote cancer cell and tumor growth [13,14]. Secondly, it is possible that the association between hyperglycemia and poor survival is mediated not by tumor growth, but rather by other adverse effects of hyperglycemia, such as increased rates of infection [15,16]. Thirdly, diabetes in cancer patients may indirectly impact the cancer outcome. For instance, a previous study indicated that cancer patients with pre-existing diabetes are often treated less aggressively than those without diabetes [9]. Thus, differences in cancer treatment between patients with and without diabetes may contribute to this increased mortality.

To date, several studies have examined CRC-specific mortality among diabetic and non-diabetic patients with CRC (Table 4) [6-8,17-19]. Two large cohort studies [6,7] and one retrospective study [8] reported the association between diabetes and a higher rate of overall mortality, even after adjustment for other predictors of CRC outcome. The two large cohort studies only included patients with non-metastatic CRC and excluded patients with metastatic CRC because the 5-year survival rate for patients with metastatic CRC is poor (approximately 10%), in accordance to the assumption that diabetes affect the long-term mortality in CRC patients [6,7]. One retrospective study showed that the prognostic impact of diabetes on the overall survival was particularly significant in patients with stage II colon cancer and was attenuated in both early (stage I) and metastatic (stage IV) colon cancer patients [8]. Each of the other three studies, which included patients with both non-metastatic and metastatic CRC, did not show any association between diabetes and CRC-specific survival [17-19]. A Norwegian study of 1,194 hospital-based patients with CRC reported that DM affects only the shortterm survival of patients treated with curative intent and the shorter overall survival was associated with cardiac disease and increased age [17]. A population-based study of the Connecticut Tumor Registry of 9,395 patients with CRC reported that cormorbid DM was not associated with a risk of death from CRC and was associated with statistical significance with death from all causes, excluding CRC [18]. Moreover, in a CPS-II Nutrition Cohort study, patients with CRC and type 2 DM had a higher risk of mortality than patients with CRC and without type 2 DM, with a particularly higher risk of death from cardiovascular disease [7]. In the current study, only patients with metastatic CRC were included, and the overall survival of patients with metastatic CRC was not significantly affected by hyperglycemia or DM. Therefore, the impact of hyperglycemia or DM on survival may be attenuated in patients with metastatic CRC or obscured by the greater tumor burden. Moreover, the high mortality risk in patients with non-metastatic CRC might be related to concurrent illnesses other than cancer, such as ischemic heart disease, hypertension, chronic renal failure, and stroke. Although several previous studies, using a subgroup analysis, have suggested that diabetes has minimal negative impact on the survival of patients with metastatic CRC, this is the first study to systematically evaluate the impact of hyperglycemia on the survival in only patients with metastatic CRC receiving palliative chemotherapy. Because the survival prognosis of patients with metastatic CRC is so poor, it is difficult to definitively conclude that there is no impact of hyperglycemia on the outcomes of these patients. Two previous studies report that hyperglycemia is independently associated with shorter survival in patients with newly diagnosed glioblastoma [20] or non-small cell lung cancer [21], and survival in these patients is much shorter than in patients with metastatic CRC.

Hyperglycemia affects all major components of the innate immunity system and impairs the body’s ability to combat infection [22]. In addition, hyperglycemia adversely affects neutrophil activity, including chemotaxis, formation of reactive oxygen species, and phagocytosis of bacteria [23]. The diabetic state increases lymphocyte apoptosis and suppresses the proliferation of T-cells, due to a lower expression of adenosine kinase [24]. Furthermore, the functions of immunoglobulins and complement are attenuated by glycosylation during hyperglycemia [25]. Finally, hyperglycemia may promote the exponential growth of bacteria and increase their virulence. In the current study, the incidence of any grade, grade 3 or 4 infections, or hospitalization for infection-related AEs increased with the mean glucose level in patients with metastatic CRC who were receiving palliative chemotherapy. These infection-related AEs may delay or result in a decrease in the intensity of chemotherapy in these patients; therefore, the results suggest the need for a regular monitoring of hyperglycemia to prevent infectionrelated AEs.

The limitations of this study include its retrospective design and the relatively small sample size, which resulted in an insufficient statistical power for detailed subgroup analyses and accurate assessments of infection-related AEs. Also, there was heterogeneity in the frequency of glucose recording and the glucose measurements available were performed at random. Fasting plasma glucose, 2-hour postprandial plasma glucose, and hemoglobin A1c levels would have provided a better index for evaluating hyperglycemia during the course of the disease. Further investigation of the proposed hypotheses in this study with a larger sample size and more refined categorization might help further elucidate the relationship between hyperglycemia, survival, and infection- related AEs in patients with metastatic CRC.

Conclusion

The present study shows that hyperglycemia was not associated with shorter survival, but it was associated with infection-related AEs in patients with newly diagnosed metastatic CRC receiving palliative chemotherapy.

NOTES

Conflict of interest relevant to this article was not reported.

Acknowledgements

This research was supported by a Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education, Science, and Technology (NRF-2007-0054930).

Fig. 1.

Kaplan-Meier estimates of the overall survival (OS) in metastatic colorectal cancer patients by the mean glucose level (A) and pre-existing diabetes mellitus (B). HR, hazard ratio; CI, confidence interval; DM, diabetes mellitus.

Table 1.

Patient characteristics according to their mean glucose levels

	Quartile of mean glucose (% of patients)				p-value
	Group 1 (n=52)	Group 2 (n=51)	Group 3 (n=51)	Group 4 (n=52)	p-value
Age at diagnosis metastatic CRC (yr)					0.038
Mean±SD	59.7±12.4	60.1±9.8	63.9±11.5	67.7±9.6
Gender					0.038
Male	61.5	78.4	56.9	76.9
Female	38.5	21.6	43.1	23.1
ECOG performance status					0.082
0, 1	88.5	82.4	70.6	86.5
≥ 2	11.5	17.6	29.4	13.5
BMI (kg/m²)					0.701
< 25	76.9	70.6	66.7	73.1
≥ 25	23.1	29.4	33.3	26.9
Comorbidity conditions by CCI scale					0.007
0, 1	98.1	96.1	86.3	80.8
≥ 2	1.9	3.9	13.7	19.2
Diabetes mellitus					< 0.001
Yes	0	0	17.6	69.2
No	100	100	82.4	30.8
Hypertension					0.076
Yes	19.2	29.4	35.3	42.3
No	80.8	70.6	64.7	57.7
Location of primary tumor					0.382
Colon	50.0	45.1	58.8	59.6
Rectum	50.0	54.9	41.2	40.4
Stage					0.072
M1a	19.2	43.1	29.4	32.7
M1b	80.8	56.9	70.6	67.3
No. of palliative chemotherapies					0.598
1	59.6	52.9	58.8	63.5
2	21.2	33.3	29.4	28.8
≥ 3	19.2	13.7	11.8	7.7
Use of dexamethasone (mean±SD)
Dose (mg)	278.4±317.1	224.9±263.7	246.9±284.7	249.5±234.4	0.808
Duration (days)	22.0±21.8	23.1±25.8	25.1±28.6	28.9±43.5	0.689
Use of megestrol acetate (mean±SD)
Dose (g)	0.43±1.17	0.40±0.94	0.66±1.16	0.71±1.58	0.468
Duration (days)	17.0±28.5	25.4±49.9	33.0±54.8	39.0±78.1	0.213

CRC, colorectal cancer; SD, standard deviation; ECOG, Eastern Cooperative Oncology Group; BMI, body mass index; CCI, Charlson Comorbidity Index; M1a, metastasis confined to one organ or site (e.g., liver, lung, ovary, or non-regional node); M1b, metastases in more than one organ/site or the peritoneum.

Table 2.

Infection-related adverse events by mean glucose level

	Quartile of mean glucose (% of patients)				p-value
	Group 1 (n=52)	Group 2 (n=51)	Group 3 (n=51)	Group 4 (n=52)	p-value
Any grade	11.5	33.3	41.2	42.3	0.002
Grade 3 or 4	7.7	29.4	35.3	28.8	0.003
Hospitalization	7.7	29.4	25.5	23.1	0.025

Table 3.

Univariate and multivariate analysis of infection-related adverse events

	Any grade infection-related adverse events
	Univariate analysis		Multivariate analysis
	Patients (%)	p-value	OR (95% CI)	p-value
Age at diagnosis of metastatic CRC		0.761	-	-
< 65 (n=124)	33.1
≥ 65 (n=82)	30.5
Gender		0.749	-	-
Male (n=141)	31.2
Female (n=65)	33.8
ECOG performance status		0.847	-	-
0, 1 (n=169)	32.5
≥ 2 (n=37)	29.7
BMI (kg/m²)			-	-
< 25 (n=148)	31.8	0.890
≥ 25 (n=58)	32.8
Comorbidity conditions by CCI scale		0.025	2.54 (0.96-6.77)	0.061
0, 1 (n=186)	29.6
≥ 2 (n=20)	55.0
Diabetes mellitus		0.007	-	-
Yes (n=45)	48.9
No (n=161)	27.3
Hypertension		0.873	-	-
Yes (n=65)	30.8
No (n=141)	32.6
Location of primary tumor		0.456	-	-
Colon (n=110)	34.5
Rectum (n=96)	29.2
Stage		0.152	-	-
M1a (n=64)	25.0
M1b (n=142)	35.2
No. of palliative chemotherapies		0.636	-	-
1 (n=121)	31.4
2 (n=58)	36.2
≥ 3 (n=27)	25.9
Use of dexamethasone
Dose	-	0.035	-	-
Duration	-	0.003	1.02 (1.00-1.03)	0.008
Use of megestrol acetate
Dose	-	0.038	-	-
Duration	-	0.016	-	-
Mean glucose level (mg/dL)		0.002	0.23 (0.09-0.58)	0.002
Group 1 (n=52)	11.5
Group 2 (n=51)	33.3
Group 3 (n=51)	41.2
Group 4 (n=52)	42.3

OR, odds ratio; CI, confidence interval; CRC, colorectal cancer; ECOG, Eastern Cooperative Oncology Group; BMI, body mass index; CCI, Charlson Comorbidity Index; M1a, metastasis confined to one organ or site (e. g., liver, lung, ovary, or non-regional node); M1b, metastases in more than one organ/site or the peritoneum.

Table 4.

Studies of the association between diabetes and outcomes of patients with colorectal cancer

References	Study design	Patients	No. of patients	Survival (diabetics vs. non-diabetics)	p-value	Subgroup analysis
Meyerhardt et al. [6]	A cohort study within a large, randomized adjuvant chemotherapy trial	High risk stage II and III colon cancer	3,759	5-yr OS; 57% vs. 66%	< 0.001	-
Meyerhardt et al. [6]		High risk stage II and III colon cancer	3,759	5-yr DFS; 48% vs. 59%	< 0.001
Dehal et al. [7]	The CPS-II Nutrition Cohort, a prospective study	Non-metastatic CRC	2,278	5-yr OS; 68% vs. 78%	< 0.001	-
				5-yr CRC-specific OS; 82% vs. 87%	0.04
				5-yr CVD-specific OS; 93% vs. 97%	< 0.001
Huang et al. [8]	A retrospective study	Stage I-IV colon cancer	2,762	5-yr OS; 48.9% vs. 56.4%	0.001	Stage I (p=0.831) Stage II (p < 0.001) Stage III (p=0.049) Stage IV (p=0.508)
Jullumstro et al. [17]	A Norwegian retrospective study	Stage I-IV CRC	1,194	5-yr CRC-specific OS; 73% vs. 79%	NS	Non-metastatic CRC (46% vs. 65%, p < 0.01)
Polednak [18]	A population-based study of the Connecticut Tumor Registry	Stage I-IV CRC	9,395	HR for death from CRC; 1.06 (95% CI, 0.94-1.20)	NS	HR for death from all causes excluding CRC; 1.84 (95% CI, 1.65-2.06)
Noh et al. [19]	A retrospective study	Stage I-IV CRC	657	5-yr OS; 68.8% vs. 75.0%	0.498	-
Present case	A retrospective study	Metastatic CRC	206	Median OS; 22.6 mo vs. 20.1 mo vs. 18.9 mo vs. 17.9 mo (by mean glucose quartiles)	0.643	-
Present case	A retrospective study	Metastatic CRC	206	Median OS; 20.5 mo vs. 19.7 mo (by pre-existing DM)	0.707

OS, overall survival; DFS, disease free survival; CPS-II, Cancer Prevention Study-II; CRC, colorectal cancer; CVD, cardiovascular disease; HR, hazard ratio; CI, confidence interval; DM, diabetes mellitus.

REFERENCES

1. Kim SG, Choi DS. The present state of diabetes mellitus in Korea. J Korean Med Assoc. 2008;51:791–8. Article
2. Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat. 2013;45:1–14. Article PubMed PMC PDF
3. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010;60:207–21. Article PubMed
4. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005;293:194–202. Article PubMed
5. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:1679–87. Article PubMed
6. Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB 3rd, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 2003;21:433–40. Article PubMed
7. Dehal AN, Newton CC, Jacobs EJ, Patel AV, Gapstur SM, Campbell PT. Impact of diabetes mellitus and insulin use on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol. 2012;30:53–9. Article PubMed
8. Huang YC, Lin JK, Chen WS, Lin TC, Yang SH, Jiang JK, et al. Diabetes mellitus negatively impacts survival of patients with colon cancer, particularly in stage II disease. J Cancer Res Clin Oncol. 2011;137:211–20. Article PubMed
9. van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, Dercksen MW, Coebergh JW, Haak HR. Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer. 2007;120:1986–92. Article PubMed
10. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83. Article PubMed
11. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and metaanalysis. JAMA. 2008;300:2754–64. Article PubMed PMC
12. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001;285:885–92. Article PubMed
13. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr. 2007;86:s836–42. Article PubMed
14. Tran TT, Naigamwalla D, Oprescu AI, Lam L, McKeown-Eyssen G, Bruce WR, et al. Hyperinsulinemia, but not other factors associated with insulin resistance, acutely enhances colorectal epithelial proliferation in vivo. Endocrinology. 2006;147:1830–7. Article PubMed
15. Muller LM, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AI, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005;41:281–8. Article PubMed
16. Turina M, Fry DE, Polk HC Jr. Acute hyperglycemia and the innate immune system: clinical, cellular, and molecular aspects. Crit Care Med. 2005;33:1624–33. Article PubMed
17. Jullumstro E, Kollind M, Lydersen S, Edna TH. Diabetes mellitus and outcomes of colorectal cancer. Acta Oncol. 2009;48:361–7. Article PubMed
18. Polednak AP. Comorbid diabetes mellitus and risk of death after diagnosis of colorectal cancer: a population-based study. Cancer Detect Prev. 2006;30:466–72. Article PubMed
19. Noh GY, Hwang DY, Choi YH, Lee YY. Effect of diabetes mellitus on outcomes of colorectal cancer. J Korean Soc Coloproctol. 2010;26:424–8. Article PubMed PMC
20. Derr RL, Ye X, Islas MU, Desideri S, Saudek CD, Grossman SA. Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009;27:1082–6. Article PubMed PMC
21. Luo J, Chen YJ, Chang LJ. Fasting blood glucose level and prognosis in non-small cell lung cancer (NSCLC) patients. Lung Cancer. 2012;76:242–7. Article PubMed
22. Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci. 2000;67:291–300. Article PubMed
23. Marhoffer W, Stein M, Maeser E, Federlin K. Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care. 1992;15:256–60. Article PubMed
24. Sakowicz-Burkiewicz M, Kocbuch K, Grden M, Szutowicz A, Pawelczyk T. Diabetes-induced decrease of adenosine kinase expression impairs the proliferation potential of diabetic rat T lymphocytes. Immunology. 2006;118:402–12. Article PubMed PMC
25. Peake PW, Charlesworth JA, Timmermans V, Gavrilovic L, Pussell B. Does non-enzymatic glycosylation affect complement function in diabetes? Diabetes Res. 1989;11:109–14. PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Glucocorticoid-Induced Hyperglycemia in Oncologic Outpatients: A Narrative Review Using the Quadruple Aim Framework
Ihab Kandil, Erin Keely
Canadian Journal of Diabetes.2022; 46(7): 730. CrossRef
Association of Comorbid Diabetes With Clinical Outcomes and Healthcare Utilization in Colorectal Cancer Survivors
Susan Storey, Zuoyi Zhang, Xiao Luo, Diane Von Ah, Megan Metzger, Jie Zhang, Amrutha Jakka, Kun Huang
Oncology Nursing Forum.2021; 48(2): 195. CrossRef
The influence on survival of glucocorticoid induced diabetes in cancer patients with metastatic spinal cord compression
Helga Schultz, Ulrik Pedersen-Bjergaard, Andreas Kryger Jensen, Svend Aage Engelholm, Peter Lommer Kristensen
Clinical and Translational Radiation Oncology.2018; 11: 19. CrossRef
Measurement of Hyperglycemia and Impact on Health Outcomes in People With Cancer: Challenges and Opportunities
Susan Storey, Diane Ah, Marilyn Hammer
Oncology Nursing Forum.2017; 44(4): E141. CrossRef
Glycemic modulation in neuro-oncology: experience and future directions using a modified Atkins diet for high-grade brain tumors
Roy E. Strowd, Mackenzie C. Cervenka, Bobbie J. Henry, Eric H. Kossoff, Adam L. Hartman, Jaishri O. Blakeley
Neuro-Oncology Practice.2015; 2(3): 127. CrossRef
The Role of Glucose Modulation and Dietary Supplementation in Patients With Central Nervous System Tumors
Roy E. Strowd, Stuart A. Grossman
Current Treatment Options in Oncology.2015;[Epub] CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Impact of Hyperglycemia on Survival and Infection-Related Adverse Events in Patients with Metastatic Colorectal Cancer Who Were Receiving Palliative Chemotherapy

Cancer Res Treat. 2014;46(3):288-296. Published online July 15, 2014

DOI: https://doi.org/10.4143/crt.2014.46.3.288

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusion
NOTES
REFERENCES

Longitudinal Comparative Analysis of Circulating Tumor DNA and Matched Tumor Tissue DNA in Patients with Metastatic Colorectal Cancer Receiving Palliative First-Line Systemic Anti-Cancer Therapy

Impact of Hyperglycemia on Survival and Infection-Related Adverse Events in Patients with Metastatic Colorectal Cancer Who Were Receiving Palliative Chemotherapy

Fig. 1. Kaplan-Meier estimates of the overall survival (OS) in metastatic colorectal cancer patients by the mean glucose level (A) and pre-existing diabetes mellitus (B). HR, hazard ratio; CI, confidence interval; DM, diabetes mellitus.

Fig. 1.

Impact of Hyperglycemia on Survival and Infection-Related Adverse Events in Patients with Metastatic Colorectal Cancer Who Were Receiving Palliative Chemotherapy

	Quartile of mean glucose (% of patients)				p-value
	Group 1 (n=52)	Group 2 (n=51)	Group 3 (n=51)	Group 4 (n=52)	p-value
Age at diagnosis metastatic CRC (yr)					0.038
Mean±SD	59.7±12.4	60.1±9.8	63.9±11.5	67.7±9.6
Gender					0.038
Male	61.5	78.4	56.9	76.9
Female	38.5	21.6	43.1	23.1
ECOG performance status					0.082
0, 1	88.5	82.4	70.6	86.5
≥ 2	11.5	17.6	29.4	13.5
BMI (kg/m²)					0.701
< 25	76.9	70.6	66.7	73.1
≥ 25	23.1	29.4	33.3	26.9
Comorbidity conditions by CCI scale					0.007
0, 1	98.1	96.1	86.3	80.8
≥ 2	1.9	3.9	13.7	19.2
Diabetes mellitus					< 0.001
Yes	0	0	17.6	69.2
No	100	100	82.4	30.8
Hypertension					0.076
Yes	19.2	29.4	35.3	42.3
No	80.8	70.6	64.7	57.7
Location of primary tumor					0.382
Colon	50.0	45.1	58.8	59.6
Rectum	50.0	54.9	41.2	40.4
Stage					0.072
M1a	19.2	43.1	29.4	32.7
M1b	80.8	56.9	70.6	67.3
No. of palliative chemotherapies					0.598
1	59.6	52.9	58.8	63.5
2	21.2	33.3	29.4	28.8
≥ 3	19.2	13.7	11.8	7.7
Use of dexamethasone (mean±SD)
Dose (mg)	278.4±317.1	224.9±263.7	246.9±284.7	249.5±234.4	0.808
Duration (days)	22.0±21.8	23.1±25.8	25.1±28.6	28.9±43.5	0.689
Use of megestrol acetate (mean±SD)
Dose (g)	0.43±1.17	0.40±0.94	0.66±1.16	0.71±1.58	0.468
Duration (days)	17.0±28.5	25.4±49.9	33.0±54.8	39.0±78.1	0.213

	Quartile of mean glucose (% of patients)				p-value
	Group 1 (n=52)	Group 2 (n=51)	Group 3 (n=51)	Group 4 (n=52)	p-value
Any grade	11.5	33.3	41.2	42.3	0.002
Grade 3 or 4	7.7	29.4	35.3	28.8	0.003
Hospitalization	7.7	29.4	25.5	23.1	0.025

	Any grade infection-related adverse events
	Univariate analysis		Multivariate analysis
	Patients (%)	p-value	OR (95% CI)	p-value
Age at diagnosis of metastatic CRC		0.761	-	-
< 65 (n=124)	33.1
≥ 65 (n=82)	30.5
Gender		0.749	-	-
Male (n=141)	31.2
Female (n=65)	33.8
ECOG performance status		0.847	-	-
0, 1 (n=169)	32.5
≥ 2 (n=37)	29.7
BMI (kg/m²)			-	-
< 25 (n=148)	31.8	0.890
≥ 25 (n=58)	32.8
Comorbidity conditions by CCI scale		0.025	2.54 (0.96-6.77)	0.061
0, 1 (n=186)	29.6
≥ 2 (n=20)	55.0
Diabetes mellitus		0.007	-	-
Yes (n=45)	48.9
No (n=161)	27.3
Hypertension		0.873	-	-
Yes (n=65)	30.8
No (n=141)	32.6
Location of primary tumor		0.456	-	-
Colon (n=110)	34.5
Rectum (n=96)	29.2
Stage		0.152	-	-
M1a (n=64)	25.0
M1b (n=142)	35.2
No. of palliative chemotherapies		0.636	-	-
1 (n=121)	31.4
2 (n=58)	36.2
≥ 3 (n=27)	25.9
Use of dexamethasone
Dose	-	0.035	-	-
Duration	-	0.003	1.02 (1.00-1.03)	0.008
Use of megestrol acetate
Dose	-	0.038	-	-
Duration	-	0.016	-	-
Mean glucose level (mg/dL)		0.002	0.23 (0.09-0.58)	0.002
Group 1 (n=52)	11.5
Group 2 (n=51)	33.3
Group 3 (n=51)	41.2
Group 4 (n=52)	42.3

References	Study design	Patients	No. of patients	Survival (diabetics vs. non-diabetics)	p-value	Subgroup analysis
Meyerhardt et al. [6]	A cohort study within a large, randomized adjuvant chemotherapy trial	High risk stage II and III colon cancer	3,759	5-yr OS; 57% vs. 66%	< 0.001	-
Meyerhardt et al. [6]		High risk stage II and III colon cancer	3,759	5-yr DFS; 48% vs. 59%	< 0.001
Dehal et al. [7]	The CPS-II Nutrition Cohort, a prospective study	Non-metastatic CRC	2,278	5-yr OS; 68% vs. 78%	< 0.001	-
				5-yr CRC-specific OS; 82% vs. 87%	0.04
				5-yr CVD-specific OS; 93% vs. 97%	< 0.001
Huang et al. [8]	A retrospective study	Stage I-IV colon cancer	2,762	5-yr OS; 48.9% vs. 56.4%	0.001	Stage I (p=0.831) Stage II (p < 0.001) Stage III (p=0.049) Stage IV (p=0.508)
Jullumstro et al. [17]	A Norwegian retrospective study	Stage I-IV CRC	1,194	5-yr CRC-specific OS; 73% vs. 79%	NS	Non-metastatic CRC (46% vs. 65%, p < 0.01)
Polednak [18]	A population-based study of the Connecticut Tumor Registry	Stage I-IV CRC	9,395	HR for death from CRC; 1.06 (95% CI, 0.94-1.20)	NS	HR for death from all causes excluding CRC; 1.84 (95% CI, 1.65-2.06)
Noh et al. [19]	A retrospective study	Stage I-IV CRC	657	5-yr OS; 68.8% vs. 75.0%	0.498	-
Present case	A retrospective study	Metastatic CRC	206	Median OS; 22.6 mo vs. 20.1 mo vs. 18.9 mo vs. 17.9 mo (by mean glucose quartiles)	0.643	-
Present case	A retrospective study	Metastatic CRC	206	Median OS; 20.5 mo vs. 19.7 mo (by pre-existing DM)	0.707

Table 1. Patient characteristics according to their mean glucose levels

Table 2. Infection-related adverse events by mean glucose level

Table 3. Univariate and multivariate analysis of infection-related adverse events

Table 4. Studies of the association between diabetes and outcomes of patients with colorectal cancer